Pfizer (NYSE:PFE) has been no stranger to the kind of damage that blockbuster drug patent expirations can inflict. The company's high-flying cholesterol fighter, Lipitor, has struggled since losing its patent protection recently, and the drug's sales have plummeted as a result. While Pfizer's done a good job bouncing back from Lipitor's losses, it's time to look into this health care giant's future to see what health care investors will be talking about for years to come.
Pfizer boasts one of big pharma's largest and broadest drug pipelines, but quantity isn't enough for a top stock like this. What are the brightest stars just waiting to emerge in Pfizer's pharmaceutical portfolio? In the video below, Fool contributor Dan Carroll highlights three of Pfizer's brightest emerging drugs that could set Wall Street abuzz for years to come -- and deliver solid returns year after year for your portfolio.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.